Dmitriy Zamarin
Cited by
Cited by
TOX is a critical regulator of tumour-specific T cell differentiation
AC Scott, F Dündar, P Zumbo, SS Chandran, CA Klebanoff, M Shakiba, ...
Nature 571 (7764), 270-274, 2019
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
L Galluzzi, I Vitale, S Warren, S Adjemian, P Agostinis, AB Martinez, ...
Journal for immunotherapy of cancer 8 (1), 2020
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy
D Zamarin, RB Holmgaard, SK Subudhi, JS Park, M Mansour, P Palese, ...
Science translational medicine 6 (226), 226ra32-226ra32, 2014
Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
RB Holmgaard, D Zamarin, DH Munn, JD Wolchok, JP Allison
Journal of Experimental Medicine 210 (7), 1389-1402, 2013
Influenza A virus PB1-F2 protein contributes to viral pathogenesis in mice
D Zamarin, MB Ortigoza, P Palese
Journal of virology 80 (16), 7976-7983, 2006
A single mutation in the PB1-F2 of H5N1 (HK/97) and 1918 influenza A viruses contributes to increased virulence
GM Conenello, D Zamarin, LA Perrone, T Tumpey, P Palese
PLoS pathogens 3 (10), e141, 2007
Influenza virus PB1-F2 protein induces cell death through mitochondrial ANT3 and VDAC1
D Zamarin, A García-Sastre, X Xiao, R Wang, P Palese
PLoS pathogens 1 (1), e4, 2005
A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity
L Glaser, J Stevens, D Zamarin, IA Wilson, A García-Sastre, TM Tumpey, ...
Journal of virology 79 (17), 11533-11536, 2005
Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner
RB Holmgaard, D Zamarin, Y Li, B Gasmi, DH Munn, JP Allison, ...
Cell reports 13 (2), 412-424, 2015
Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient
A Jiménez-Sánchez, D Memon, S Pourpe, H Veeraraghavan, Y Li, ...
Cell 170 (5), 927-938. e20, 2017
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
B Nguyen, C Fong, A Luthra, SA Smith, RG DiNatale, S Nandakumar, ...
Cell 185 (3), 563-575. e11, 2022
IRE1α–XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity
M Song, TA Sandoval, CS Chae, S Chopra, C Tan, MR Rutkowski, ...
Nature 562 (7727), 423-428, 2018
Attenuation of equine influenza viruses through truncations of the NS1 protein
M Quinlivan, D Zamarin, A García-Sastre, A Cullinane, T Chambers, ...
Journal of virology 79 (13), 8431-8439, 2005
Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions
D Zamarin, P Palese
Future microbiology 7 (3), 347-367, 2012
Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study
D Zamarin, RA Burger, MW Sill, DJ Powell Jr, HA Lankes, MD Feldman, ...
Journal of Clinical Oncology 38 (16), 1814, 2020
Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine
LF Campesato, S Budhu, J Tchaicha, CH Weng, M Gigoux, IJ Cohen, ...
Nature communications 11 (1), 4011, 2020
Nuclear localization of the Nipah virus W protein allows for inhibition of both virus-and toll-like receptor 3-triggered signaling pathways
ML Shaw, WB Cardenas, D Zamarin, P Palese, CF Basler
Journal of virology 79 (10), 6078-6088, 2005
Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells
M Mansour, P Palese, D Zamarin
Journal of virology 85 (12), 6015-6023, 2011
PD-1 blockade in advanced adrenocortical carcinoma
N Raj, Y Zheng, V Kelly, SS Katz, J Chou, RKG Do, M Capanu, D Zamarin, ...
Journal of Clinical Oncology 38 (1), 71, 2020
Pharmacologic modulation of RNA splicing enhances anti-tumor immunity
SX Lu, E De Neef, JD Thomas, E Sabio, B Rousseau, M Gigoux, DA Knorr, ...
Cell 184 (15), 4032-4047. e31, 2021
The system can't perform the operation now. Try again later.
Articles 1–20